Coagulation factor IV is an indicator of symptomatic pulmonary embolism in patients with primary lung cancer
- 20 November 2019
- journal article
- research article
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 14 (2) , 124-131
Abstract
Background: Coagulation factor IV, also known as serum ionised calcium (SIC), participates in coagulative process and tends to elevate in patients with primary lung cancer. It may be an indicator of symptomatic pulmonary embolism (PE) due to primary lung cancer (LC).Methods: A total of 388 patients who underwent CTPA and/or radionuclide ventilation perfusion scanning due to PE‐suspected symptoms were stratified into LCPE (lung cancer and PE) group (n = 95), PE group (n = 99), LC group (n = 98) and control group (n = 96). At admission, the level of SIC and STC (serum total calcium) was compared among four groups. At discharge, the level change of SIC and STC from admission to discharge was compared among four groups. The coefficients analysis between SIC as well as STC and the possibility of PE were performed.Results: The SIC of LCPE group was the highest among four groups at admission (P < 0.001). The level change of SIC from admission to discharge in LCPE group was the highest among four groups (P = 0.001). A ROC curve analysis demonstrated that the sensitivity and specificity of SIC for a diagnosis of PE among LC patients were 71.9% and 86.0%, respectively. The area under curve (AUC) was 0.781. Along with the increase of 0.1 mmol/L in SIC level, the risk ratio for a PE was 2.165 (1.537‐2.849) (P < 0.001).Conclusions: Serum ionised calcium may be an indicator of pulmonary embolism in patients with primary lung cancer.Keywords
This publication has 28 references indexed in Scilit:
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012
- Idraparinux versus Standard Therapy for Venous Thromboembolic DiseaseNew England Journal of Medicine, 2007
- Hypercalcemia–leukocytosis syndrome associated with lung cancerLung Cancer, 2004
- Treatment of malignancy-associated hypercalcemia and cachexia with humanized anti-parathyroid hormone-related protein antibodySeminars in Oncology, 2003
- High Plasma Levels of Factor VIII and the Risk of Recurrent Venous ThromboembolismNew England Journal of Medicine, 2000
- The Risk of Recurrent Deep Venous Thrombosis among Heterozygous Carriers of Both Factor V Leiden and the G20210A Prothrombin MutationNew England Journal of Medicine, 1999
- Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemiaThe Lancet, 1992
- Parathyroid hormone related protein and hypercalcaemia in breast cancer.BMJ, 1991
- Immunochemical Characterization of Circulating Parathyroid Hormone–Related Protein in Patients with Humoral Hypercalcemia of CancerNew England Journal of Medicine, 1990
- HYPERCALCAEMIA AND METASTATIC BONE DISEASE: IS THERE A CAUSAL LINK?The Lancet, 1982